Durvalumab and tremelimumab plus chemotherapy with propranolol
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 study tests whether adding propranolol to durvalumab and tremelimumab along with chemotherapy can help control advanced pancreatic cancer, liver cancer, or bile duct cancer. It aims to shrink tumors and help people live longer or feel better when the cancer can’t be cured with surgery or local treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh more than 30 kg
- You can be expected to live at least 12 weeks
- You have advanced pancreatic, liver (HCC), or bile duct (BTC) cancer that can’t be cured with surgery or local treatments
- You have at least one measurable tumor on scans (per specific scan rules)
- You have recovered from any radiation you had at least 4 weeks ago (side effects must be mild, grade 1 or less)
- Your blood counts, kidney function, and liver function meet required lab cutoffs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
This trial tests a combination of two drugs—durvalumab (an immunotherapy) and olaparib (a targeted therapy)—for people with advanced bile duct cancer that did not grow after initial treatment with chemotherapy and durvalumab. The goal is to see if this combination can help control the cancer further.
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.